WebJul 11, 2024 · Purpose Case reports and small prospective trials suggest that administering targeted therapies to patients with advanced cancer and an identified genomic target may be associated with clinical benefit. The Targeted Agent and Profiling Utilization Registry (TAPUR) study, a phase II prospective, nonrandomized, multibasket pragmatic clinical … WebTAPUR is designed to include a broader patient population than is typically enrolled in clinical trials. The study will include patients who have any advanced solid tumor, …
Rationale and Design of the Targeted Agent and Profiling Utilization ...
WebThe Targeted Agent and Profiling Utilization Registration (TAPUR) study Description The TAPUR study is a clinical trial that aims to improve our understanding of how … WebJul 19, 2016 · Log In ASCO.org Conquer Cancer ASCO Journals Donate eNews Signup fCancer.net on Facebook tCancer.net on Twitter qCancer.net on YouTube Home Types of Cancer Navigating Cancer Care Coping With Cancer Research and Advocacy Survivorship Blog About Us Home > Blog > Cancer.Net Podcasts > graafikko opinnot
Trastuzmab Plus Pertuzumab Targets ERBB2/ERBB3 in Uterine …
WebFeb 8, 2024 · The TAPUR Study is a phase II basket trial that aims to evaluate activity of approved targeted agents in patients with advanced cancers with potentially actionable genomic variants. Data from a cohort of patients with metastatic castrate-resistant prostate cancer (mCRPC) and BRCA1 / 2 mutations treated with olaparib are reported. METHODS WebJul 23, 2024 · TAPUR Design First launched in 2016, TAPUR (NCT02693535) is a phase 2, open-label, basket study sponsored by the American Society of Clinical Oncology … WebJun 8, 2024 · Caris Molecular Intelligence Tumor Profiling Reports Optimized to Molecularly Identify Genomic Alterations for the TAPUR Study IRVING, Texas, June 8, 2024 – Caris Life Sciences ®, a leading innovator in molecular science, and the American Society of Clinical Oncology, Inc. (ASCO®), announced that Caris is one of the first laboratories to have a … graafikko pekka loiri